An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.
Derm In The News: September 22-28
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations